Vivos Inc (RDGL)

[bdvest]

Be aware! Do the DD.
Vivos Inc (RDGL), previously known as Advanced Medical Isotope Corp
was covered by an independent analyst.
www.leeuwenhoeck.com
http://nebula.wsimg.com/4428bdde9198e981707684ab50fbc9d6?AccessKeyId=F1B3D293B900048B2E3E&disposition=0&alloworigin=1

More than a year ago, RDGL was valued by Van Leeuwenhoek Research for valuation of USD $35-$55 million or $0.66 - $1.00 per share, based on the potential market expectation and OS of 89M shares;
Right now RDGL has made great progress toward marketing its isopet for pet cancer treatment, getting drastic public exposure and will move next step to human trials, yes, the OS shares were diluted and will be around 1.5B, but the share price would still be worthy of a dime or more very soon.
Here are some important points from that report:
(1) According to the Center for Cancer
Research and CanineCancer.com an estimated six million dogs are diagnosed with cancer each year in the USA. According to various market reports, the market for pet cancer therapeutics is estimated to be USD 300-500 million.
(2)We feel that Y-90 RadioGel therefore has the potential to be a blockbuster (sales > 1 billion) within a few years since the therapy would be useful in a range of soft tissue cancers.
(3)Considering Y-90 Radiogel’s much higher potential commercial success compared to Sirtex’ SIR-Spheres (with total annual sales of more than AUD 200 million) and the high unmet medical need in several types of cancer, induces us to increase our valuation to USD 35-55 million;
(4) RDGL has selected skin cancer therapy for its first indication for use with the Food and Drug Administration. In the US there are 5.4 million cases of skin cancer in 3.3 million people. Treating 10% of these patients could generate annual revenue at greater than USD 1 billion. Vivos believes there are significant future opportunities in treating lymph nodes, prostate, breast, liver, pancreatic, head and neck cancers.
(5) The FDA has classified RadioGel as a device. This increase chances of a timely approval considerably. The critical path on the overall schedule to approval is firstly to complete laboratory testing concurrent with veterinary animal studies and then continue into human clinical trials. RDGL intends to align the animal treatments in its veterinarian business division to support the animal testing required for the FDA to synergize the two divisions, and potentially create time and cost savings. In this parallel strategy, the company looks to move to first-in-man trials as soon as possible, while aggressively pursuing near-term revenues through the veterinary division, IsoPet, and through licensing.